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Abstract: In recent years, cell adhesion and cell adhesion molecules have been shown to be important
for many normal biological processes, including embryonic cell migration, immune system functions
and wound healing. It has also been shown that they contribute to the pathogenesis of a large number
of common human disorders, such as rheumatoid arthritis and tumor cell metastasis in cancer.
In this review, the basic mechanisms of cellular adhesion and the structural and functional features of
adhesion molecules are summarized.

Introduction
Cells in vivo must form contacts with their neighbours or with an extracellular matrix (ECM)
in order to form tissues or organs. The macromolecular components of ECM, which are secreted
by resident cells, include proteglycans, glycoproteins and collagens, which may function as
tracks, directing migrating cells along a particular route. Other members of the ECM, including
adhesive molecules such as laminin, vitronectin and fibronectin, facilitate the adherence of cells
to their substratum as they migrate. ECM not only fills intercellular spaces, shaping and
strengthening many tissues, but also influences celluar functions such as state of differentiation
and proliferation (1, 2, 4). Evidence originally obtained from studies with antisera against cell
surface proteins revealed that the morphology of cells bound to the ECM could be modified and
that these cells could become de-attached by such treatments, suggesting that specific receptors
regulated the process (2). In the last 20 years, the nature of many of these cell adhesion
receptors has been elucidated, while the use of synthetic peptides or proteolytic fragments of
adhesive proteins has revealed the nature of cell-binding sites on these receptors (3, 4).
Cell adhesion receptors identified to date mediate both homophilic adhesion (which involves
binding of an adhesion molecule on one cell to the same adhesion molecule on a second cell) and
heterophilic adhesion (in which an adhesion molecule on one cell type binds to a different type
of cell adhesion molecule on a second cell). The T-cell interaction with antigen-presenting target
cells in the immune system is the best known example of heterophilic adhesion (4). Many
different molecules have been identified by using specific monoclonal antibodies (mAbs) and the
subsequent identification of genes responsible for encoding these molecules has shown that they
are structurally different from each other. These cell adhesion molecules can be divided into 4
major families: the cadherin superfamily, the selectins, the immunoglobulin superfamily and the
1
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integrins (2-5). The interactions of these cell adhesion with the ECM are important for
development processes as diverse as the differentiation of tissues, morphogenesis and the
development of metastases. During embryogenesis, for example, adhesion mediated by cell
adhesion receptors to fibronectin is essential for cell motility, which is involved in the migration
of neural crest and primordial germ cells (1). When mammary epithelial cells were cultured only
on reconstituted basement membrane or on collagen gels, they became polarised and produced
milk proteins, suggesting that ECM-receptor interactions also are involved in determining the
differentiation of tissues (6). In malignant disease, the adhesive interactions of tumour cells with
other cells or with the ECM are thought to regulate invasive and metastatic behaviour. Several
lines of evidence have been used to demonstrate the involvement of altered expression of
adhesion molecules in some of the events of the metastatic process. For example, downregulation or loss of α5β1 integrin expression from neoplastic cells seems to be associated with
increased tumorigenicity in nude mice (7). In addition, down-regulation of E-cadherin was found
in many carcinomas, such as in those of the head and neck region (8, 9), the thyroid (10), the
lungs (11) and the prostate (12, 13).
The Cadherins
One group of cell adhesion molecules implicated in tissue formation are the Ca2+Ð depentent,
developmentally regulated, transmembrane proteins termed cadherins (8-14). Cadherins
expressed on one cell can bind to a matching cadherin expressed on a neighbouring cell, co
cadherins interact in a homophilic fashion (5). However, more recent studies have revealed that
various types of cadherin can also interact with other cell adhesion family members, such as
integrins and proteglycans, in a heterophilic fashion. For example, E-cadherin on epithelial cells
binds to the αEβ7 integrin expressed on T-lymphocytes (15). Cadherins contain a short
transmembrane domain and a relatively long extracellular domain containing four cadherin
repeats (EC1-EC4), each of which contains calcium binding sequences. The structural features
of cadherins are demonstrated in Figure 1. The cytoplasmic domain is highly conserved region
between cadherin molecules, implying that it has an important function. Cadherins interact with
specific cytoplasmic proteins, e.g., catenins (α, β and γ) (16), as a means of being linked to the
actin cytoskeleton. The binding of cadherins to the catenins is crucial for cadherin function, and
the deletion of specific sites in the cytoplasmic domain of the cadherins inhibits the interaction
between cadherins and catenin, with the result that the cadherins become nonadhesive. As a
consequence of this interaction with catenins, the cadherins are able to form cell junctions, which
are important for epithelial cell polarity (17, 18, 20). Many different cadherins have been
described, the main ones being neural cadherin (N-cadherin), placental cadherin (P-cadherin) and
epithelial cadherin (E-cadherin). Each cadherin shows a specific tissue distribution during
development and adult life. For example, N-cadherin is the predominant cadherin of neural
tissues, but is also expressed on cardiac and skeletal muscle cells, where it maintains the stucture
of intercalated discs between neighbouring muscle cells (19). The permanent expression of Pcadherin is limited to the epidermis, mesothelium and corneal epithelium (20), and E-cadherin
expression is restricted to non-neural epithelial tissues (21).
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E-cadherin is thought to be important during embryonic development, and is also involved
in generating and maintaining epithelial layers in adult tissues (22). Furthermore, the loss of Ecadherin expression has been linked to the invasive behaviour of tumour cells. When kidney
epithelial cells, which express E-cadherin and are non-invasive, are transfected with oncogenes,
they become invasive and show the loss of E-cadherin expression on their cell surface. Similar
results have been obtained by using anti-E-cadherin antibodies to inhibit E-cadherin activity on
non-transformed kidney epithelial cells (17, 18). Many cancer types, such as breast, stomach
and colorectal cancer, have been shown by immunohistochemical techniques to exhibit loss or
down-regulation of E-cadherin expression (23). In prostate cancer, E-cadherin expression is
down-regulated or absent in approximately 50% of tumours. However, there are many reports
indicating that some epithelial tumours show no indication of down-regulation or loss of Ecadherin expression (24, 25). Certain metastatic deposits of prostate carcinoma have been
shown to exhibit high surface expression of E-cadherin, and the levels of E- and P-cadherins
expression are unchanged in the primary tumors or their metastases. However, down-regulation
at the protein level is not the only way that cadherin function can be impaired. Interaction of
cadherins with abnormal catenins may cause the loss of cadherin mediated cell adhesion, while
mutations in the cadherin can also result in a similar loss of function (25).
The Selectins
Selectins, a family of Ca+2Ðdependent carbohydrateÐbinding proteins, mediate the initial
attachment of leukocytes to the endothelium on the blood vessel wall during the rolling step of
leukocyte extravasation in inflammation (2, 4). Selectins recognise fucosylated carbohydrate
ligands, especially structures containing SialylÐLewisx (sLex) and SialylÐLewisa (sLea), which are
heavily expressed on neutrophils and monocytes (26) and also found on natural killer cells.
These selectin/carbohydrate interactions permit leukocytes to roll along the vascular
endothelium in the direction of blood flow as a prelude to integrinÐmediated adhesion.
Structural features of selectins (Figure 2) include the presence of NH2Ðterminal CÐtype
Ca2+Ðdependent lectinÐlike binding domain, which determines the ability of each selectin to bind
to specific carbohydrate lingands, an epidermal growth factorÐlike region and a number of
repeat sequences similar to those found in complement regulatory proteins (CRP). This is
followed by a membraneÐspanning region and a short cytoplasmic region. The lectin and
EGFÐlike domains are shown to have 60% to 70% homology at the nucleotide and protein level
to each other (26, 27). The selectins include a group of three related molecules. E
(endothelial)Ðselectin in expressed on endothelial cells where its synthesis is increased rapidly
after cell stimulation by cytokines (TNFÐα and ILÐ1) or endotoxin and then is translocated to
the luminal surface of the venular endothelium (28). Because carbohydrate ligands such as sLea,
a ligand for EÐselectin, are expressed on some tumour cells but are not usually found on
leukocytes, this interaction between EÐselectin and sLea is more relevant to tumour metastases
than to leukocyte trafficking. For example, EÐselectin has been found to regulate adhesion of
human colon cancer cells to the endothelium by binding to sLea and sLex carbohydrate ligands
(26, 27).
3

Cellular Adhesion and Adhesion Molecules

α
COOH
NH2

Pre-region

EC1

EC2

EC3

EC4
β

γ

Catenins
Calcium binding sequence
Transmembrane domain
Cytoplasmic domain which interacts with catenins

Fig. 1.

Structural features of cadherin molecules.

NH2

COOH

Lectin domain
EGF-like domain
Complement regulatory-like domain
Transmembrane domain
Cytoplasmic domain

Fig. 2.

Schematic diagram of selectin molecule.

PÐselectin is another type of selectin adhesion protein that initially was found in platelets and
also is constitutively expressed in endothelial cells (29, 30). In both cell types, PÐselectin is
synthesised and stored in cytoplasmic granules; in platelets PÐselectin is contained in the
αÐgranules, whereas in endothelial cells it is found in WiebelÐPalade bodies. PÐselectin is
mobilised rapidly to the external plasma membrane of endothelial cells and platelets in response
to activation with cytokines such as thrombin (30). Expression of PÐselectin on the cell surface
generally is shortÐlived, which supports the idea that this selectin mediates early
leukocyteÐendothelial interactions and also mediates the binding of activated BÐcells, and a
subset of TÐcells, to stimulated endothelium in vitro. Recently it has been shown that PÐselectin
expressed on platelets regulates their binding to tumour cells and that this phenomenon can
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prevent tumour cell destruction by immune mechanisms owing to the formation of aggregates
(29, 30, 31).
Unlike EÐ and PÐselectins, LÐselectin is found only on leukocytes and is expressed
continuously throughout myeloid differentiation and on early erythroid progenitor cells but not
on mature erythrocytes (30). Although originally LÐselectin was reported to mediate lymphocyte
binding to high endothelial venules (HEV) of peripheral lymph nodes during lymphocyte homing,
it subsequently was shown to be expressed on most other peripheral blood leukocytes and is
thought to be involved in regulating leukocyte traffic in the systemic microcirculation (28). Some
blood cells, such as lymphocytes and neutrophils, have shown a loss of LÐselectin expression
after activation (32) due to proteolytic cleavage near the site of membrane insertion. Loss of
LÐselectin from the surface of leukocytes inhibited leukocyte adhesion to cytokineÐstimulated
endothelium and was able to prevent leukocytes homing to inflammatory sites in vivo (33).
Recently elevated levels of LÐselectin have been observed in the serum of patients with AIDS and
leukemia (34) and it may be that the presence of this molecule has an impact upon the
trafficking of normal and neoplastic cells.
Immunoglobulin Superfamily Adhesion Molecules
The immunoglobulin superfamily contains many cell adhesion molecules (Figure 3). The
structure of this family of adhesion receptors is characterised by repeated domains, similar to
those found in immunoglobulins. By mutation and deletion analysis these immunoglobulin
domains have been shown to mediate many different functions, including acting as receptors for
growth factors and mediating cellÐcell adhesion rather than cellÐECM interactions (35, 36).
Though not all immunoglobulinÐsuperfamily adhesion molecules mediate cellÐcell interactions,
many which belong to this family do function as adhesion receptors, including intercellular

NH2

COOH

Immunoglobulin-like extracellular domain

LFA-1 binding site
Mac-1 binding site
Transmembrane domain
Cytoplasmic domain

Fig. 3.

A member of immunoglobulin superfamily was shown as a schematic diagram.
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adhesion moleculeÐ1 (ICAMÐ1; CD54), intercellular adhesion moleculeÐ2 (ICAMÐ2), vascular cell
adhesion moleculeÐ1 (VCAMÐ1; CD106), plateletÐendothelial cell adhesion moleculeÐ1
(PECAMÐ1; CD31) and the mucosal addressin cell adhesion moleculeÐ1 (MAdCAMÐ1). ICAMÐ1,
ICAMÐ2 and VCAMÐ1 are involved in the adhesion of T cells to endothelial cells by serving as
surface ligands for the integrins LFAÐ1 (leukocyteÐfunction antigenÐ1; αLβ2) and α4β1 (36).
Some adhesion receptors of the immunoglobulin superfamily are very restricted in their patterns
of expression. Thus the neural cell adhesion molecule (CEA) is found on cells of the
gastrointestinal tract. However, other members of this immunoglobulin superfamily are not
restricted. Thus ICAM,1 is expressed on a variety of haematopoietic and nonhaematopoietic
cells, including B and T cells, fibroblasts, keratinocytes and endothelial cells, where the level of
expression can be upregulated by various cytokines (37, 38).
(i) ICAM-1 and ICAM-2
The adhesion molecules ICAM-1 and ICAM-2 (CD102) are counter-receptors for the
leukocyte β2 integrin, LFA-1 (CD11a/CD18). Amino acid substitutions in the extracellular
domains have indicated that the primary binding site for LFA-1 is located in the NH2-terminal
first domain of ICAM-1 (38). A recent report has shown that a second ligand-binding site for
another β2 integrin on leukocytes (CD11b/CD18, Mac-1) is localised to the third
immunoglobulin-like domain. Because ICAM-2 has only two extracellular immunoglobulin-like
domain. Because ICAM-2 has only two extracellular immunoglobulin-like domains and, as
mentioned above, the binding site for Mac-1 is localised to the third immunoglobulin-like domain
of ICAM-1, it appears that ICAM-2 does not serve as an endothelial ligand for this leukocyte
integrin (38, 39). ICAM-1 is expressed on leukocytes, fibroblasts, epithelial cells and endothelial
cells where its expression can be induced by cytokines such as TNF-α and IL-1β (40). ICAM-2
also has a similar tissue distribution to ICAM-1, but apparently is expressed constitutively and is
not regulated by cytokines. A portion of the cytoplasmic region of ICAM-1 has been shown to
bind to the cytoskeleton of COS cells transfected with the cDNA of human ICAM-1 (38, 40, 41).
Linkage with the cytoskeleton may localise ICAM-1 within regions of the endothelial cell
membrane in order to facilitate leukocyte adherence and transmigration (41). The expression of
ICAM-1 in primary melanoma is related to the presence of distant metastases (42). The precise
involvement of ICAM-1 in the process of metastasis is not yet clear. Elevated levels of soluble
ICAM-1, which still retains the binding site for LFA-1 in its extracellular domain, have been found
in the serum of melanoma and ovarian cancer patients (43). It has been suggested that this
active form of ICAM-1 can inhibit binding sites on cytotoxic T-cell and natural killer cells and that
in its presence therefore tumour cells might better be able to escape immune destruction (42,
43). Because human melanoma cells have been shown to release ICAM-1, and its increased level
in serum results in a non-specific inflammatory response, it has been suggested that circulating
levels of ICAM-1 reflect the formation of metastases, possibly as a consequence of facilitating
disseminating tumour cell binding (43).
(ii) VCAM-1
Another member of the immunoglobulin gene superfamily, VCAM-1, is a 90-110 kDa
glycoprotein expressed on the surface of activated endothelium and a variety of other cell types,
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including dendritic cells, tissue macrophages and bone marrow fibroblasts. VCAM-1 expression
on endothelial cells can be up-regulated by several cytokines, such as IL-1β, IL-4, TNF-α and
interferon-γ (IFN-γ) (36, 44). VCAM-1 interacts with the leukocyte integrin α4β1 on many
different cells including eosinophils, monocytes (and also certain tumour cells, as will be
discussed below) and with α4β7 on activated peripheral T cells (45). Thus α4β1/VCAM-1
interactions, like LFA-1/ICAM-1 interactions, may regulate the movement of lymphocytes out of
blood vessels to inflammatory sites. Furthermore, an α4β1/VCAM-1 interaction has been shown
to be crucial for the binding of haematopoietic precursor cells to bone marrow stroma (46, 47),
the binding of lymphocytes to dendritic cells (47) and the generation of secondary myoblasts
(48). Interaction of VCAM-1 with α4β1 integrin expressed on certain tumour types has also
been suggested to be an important mechanism for the development of metastases in cancers
such as melanomas, osteosarcomas, neuroblastomas and rhabdomyosarcomas (49).
(iii) PECAM-1
The platelet-endothelial cell adhesion molecule PECAM-1, also knows as CD31 or endoCAM,
is a 130kDa glycoprotein found on endothelial cells, on platelets and on some leukocytes such
as monocytes and neutrophils (50). Several observations suggest that PECAM-1 could be
involved in leukocyte adhesion and particularly in leukocyte transmigration and particularly in
the preferential migration of naive and CD8+ T cells across HEV (36). PECAM-1 is homologous
to both CEA and ICAM-1 proteins and has been shown to contribute to both homotypic and
heterotypic cell adhesion by interaction with either itself or the integrin αvb3 (51, 52). Unlike
ICAM-1, which is expressed over the entire surface of resting endothelial cells, PECAM-1 is
expressed at intercellular junctions of endothelial cells and the surface expression of PECAM-1
is not increased by treatment with cytokines, such as TNF-α and IL-1 or by combinations of
TNF-α and IFN-γ (50). Binding of mAbs to PECAM-1 enhanced CD8+ T-cell adhesion to
fibronectin or VCAM-1, but not to fibrinogen or collagen, suggesting that it may cause activation
of integrins containing α4 subunits such as α4β1 or α4β7 (51, 53). Inhibition of PECAM-1
expression on leukocytes or endothelial cells by treatment with soluble PECAM-1 or blocking
PECAM-1 mAbs has been shown to inhibit monocyte or neutrophil transmigration in vitro.
Treatment of either the endothelium or the leukocytes separately is equally effective, suggesting
that homophilic adhesive interaction is involved (54).
Integrins
Integrins are a major family of cell surface receptors that are responsible for anchoring cells
to ECM, and that function as cell-cell adhesion molecules. They also act as regulatory receptors
that can initiate intracellular signal pathways (55, 56). Several recent studies have shown that
integrins influence a variety of dynamic processes during embryonic development, tissue
organisation and inflammation by affecting cell migration, proliferation, differentiation and gene
expression. These molecules also might serve as targets for the therapy of certain diseases, such
as leukocyte adhesion deficiency (LAD), resulting from a structural defect in the β2 subunit (57),
and GlanzmannÕs thrombasthenia, which is a defect or deficiency in αIIbβ3 (58).
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The integrin family is composed of heterodimers consisting of two non-covalently associated
subunits, α and β, both of which are necessary for adhesive binding. The integrins can be
classified into four distinct subfamilies based on a common β subunit: β1 integrin (very late
activation antigens (VLA) proteins), β2 integrin (Leu CAMs), β3 integrins (cytoadhesins) and β7
integrins (homing). Fifteen different α and eight different β subunits give rise to over twently
different αβ heterodimeric combinations at cell surfaces (Figure 4). Both the α and β subunit
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Structure of α and β subunits of integrins.
Lam, laminin; Coll, collagen; Fn, fibronectin; Fn-RGD, RGD binding site in Fn; Fn-CS1 denotes binding to the
CS1 splice insert of fibronectin; VCAM-1, vascular cell adhesion molecule 1; Vn, vitronectin; Fb, fibrinogen;
VWF, von willebrand factor; TS, thrombospondin; OP, osteopontin; ICAM-1,2,3, intercellular cell adhesion
molecules; iC3b, inactivated C3b component of comlement; FX, coagulation factor X.
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of integrins are membrane glycoproteins with a large extracellular domain, a single
transmembrane domain and a short cytoplasmic domain. Typically, the α subunits, which have
a molecular weight range from 150 to 200 kDA, display lower sequence homology than do the
β subunits. The N-terminal of the α subunit contains 3 or 4 divalent cation binding sites which
resemble the ÒEF handÓ consensus structure found in other calcium-binding proteins, e.g.,
calmodulin or troponin-C (59). These divalent cation binding sites are essential for ligand
binding and regulation and for maintaining the association between the α and β subunits (60).
The α subunits can be divided into two groups: the first group of α subunits undergoes posttranslational α subunit cleavage (e.g., α5 and αv), whereas the other group contains an extra
180-200 amino acids inserted between repeats 2 and 3 (Figure 5), known as the I domain or
inserted domain (e.g., α1, α2, αL, αM and αX). Except for the α4 subunit, which will be
discussed later, the α subunits in group one have four putative cation sites. The group two α
subunit, however, has three divalent cation sites (61).
The C-terminal cytoplasmic domains of α subunits are small (15 to 77 amino acids). Apart
from the membrane-proximal sequence GFFKR, which is highly conserved between α subunits,
the subunits of remaining sequence have limited homology to one another, suggesting that each
type of subunit has unique cytoskeletal interactions. However, various species can show a high
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Fig. 5.

Association between the known α and β integrin subunits and the ligands with which they interact.
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degree of homology between the C-terminal cytoplasmic domains of similar α subunits. For
instance, 31 of the 36 C-terminal amino acids of α3 from the human have been found to be
identical to α3 from the chicken.
Cloning and sequencing studies of the human integrin β1 (62), β2 (63) and β3 (64) have
revealed strong homology at amino acid levels of 40-48%. All β subunits, which molecular
weights of between 90 and 130kDa, except for β4 (210kDa), contain 56 conserved cysteines.
Many of these cysteines are in four repeating motifs within a cysteine-rich region in the
extracellular domains of β1, β2 and β3 subunits. The cytoplasmic domain of the β subunits is
short (40-50 amino acids), with the exception again being β4, which contains a long cytoplasmic
domain of 1018 amino acids containing four fibronectin type III repeats (65).
Quantitative analyses of cell adhesion have implicated the cytoplasmic region of α and β
subunits, which are anchored to cytoskeletal structures in the cell, as contributing to the
regulation of adhesion. Recent studies have revealed that integrin subunits transmit signals from
the extracellular matrix to the cell interior (outside-in) and from the inside of the cell to the
outside of the cell (inside-out), similar to those transduced by growth factors, hormones and
cytokines (66). Integrin signaling regulates cell proliferation, differentiation and survival as well
as cell adhesion. Mutation studies of the cytoplasmic domain of β1 integrins (67) have shown
that this region of the integrin is important for integrin-mediated cell adhesion and the
localisation of integrins to the focal contacts. In platelets, fibroblasts and carcinomas, the binding
of soluble ligands, e.g., fibrinogen to activate αIIbβ3 integrin, causes tyrosine phosphorylation
of several different proteins, including focal adhesion kinase (FAK) (55, 67). Changes in
intracellular pH and calcium, the release of lipid second messengers, the activation of PKC and
the activation of phosphatidyinositol-3-kinase (PI3-kinase) (68) all are caused by integrin
engagement during cell adhesion. In addition to these effects, the integrin-mediated activation
of mitogen-activated protein kinase (MAPK) (69), the activation of p21 Ras (70) and the
expression of immediate early genes by α5β1 integrin have also been demostrated, thus tying
integrin occupancy to the cell proliferation machinery. Integrin-mediated signaling has been
shown to be an important phenomenon in the context of cancer cell growth and behaviour (71).
Oncogenic transformation of cells tends not to show a complete loss of adhesion but rather a
change in the expression of certain integrins. Melanoma obeys this rule in that integrins such as
αv and β3 are shown to be expressed at high levels in malignant melanoma cells, where it is
suggested that they participate in increased invasion or metastasis (71). Blocking αvβ3 function
with anti-αv antibody inhibited both the migration of melanoma cells on vitronectin and
xenograft formation in nude mice (72, 73). In summary, it has been documented that changes
in various integrin-ligand interactions permit melanoma cells to become invasive both on
extracellular matrix substrates and in distant tissues during tumour progression.
Discussion
Cell adhesion and adhesion molecules have been shown to contribute to the pathogenesis of
a large number of common human disorders and tumor cell metastasis in cancer. Recent studies
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have demostrated that cell adhesion moleculas are involved in signal transduction pathways.
These molecules transmit signals from the extracellular matrix on the cell interior (outside-in)
and from the inside of the cell to the outside of the cell (inside-out) similar to those transduced
by growth factors, hormones and cytokines. These results might be extremely significant in
metastatic spread and the treatment of a large number of human disorders.
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